Condition

Metastatic Pancreatic Ductal Adenocarcinoma clinical trials and research

• 17Clinical trials
• 22Countries

Newest Metastatic Pancreatic Ductal Adenocarcinoma clinical trials

All recruiting trials (17)

• Pan-KRAS inhibitor JAB-23E73 with chemotherapy for metastatic pancreatic cancer with KRAS changes

  This study tests whether adding the pan-KRAS inhibitor JAB-23E73 to standard chemotherapy can help people with metastatic pancreatic cancer that has KRAS alterations.

  Recruiting at 6 sites Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 12 other locations · NCT07640295

• Combo therapy with selumetinib and trastuzumab deruxtecan for advanced pancreatic cancer

  This phase 1/2 trial tests whether the combination of selumetinib and DS-8201a (trastuzumab deruxtecan) is safe and whether it can help people with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Pittsburgh, Pennsylvania · NCT07619521

• Telisotuzumab adizutecan with FOLFOX versus standard care in first-line metastatic pancreatic cancer

  This study tests whether adding telisotuzumab adizutecan to FOLFOX helps adults with unresectable, metastatic pancreatic cancer compare to standard treatment.

  Recruiting at 22 sites Phase 2/3 AbbVie · New Haven, Connecticut and 21 other locations · NCT07490301

• Pegcetacoplan with modified FOLFIRINOX for metastatic pancreatic cancer

  This trial tests whether adding pegcetacoplan to modified FOLFIRINOX helps people with metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Roswell Park Cancer Institute · Buffalo, New York · NCT07214298

• TQB2868 plus anlotinib with chemotherapy versus placebo plus chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma

  This trial will see if adding TQB2868 injection and anlotinib capsules to first-line chemotherapy helps adults with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer than chemotherapy with placebo.

  Recruiting at 2 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 70 other locations · NCT07165951

• Using ctDNA to guide earlier switching from first-line mFOLFIRINOX in metastatic pancreatic cancer

  This will test whether a blood test (ctDNA) can tell if people with metastatic pancreatic cancer are not responding to first-line mFOLFIRINOX soon enough to switch therapies earlier than standard imaging.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07096362

• OMO-103 for advanced or metastatic pancreatic ductal adenocarcinoma

  This trial tests an experimental IV drug called OMO-103 to see if it changes tumor cells in adults with locally advanced or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT07089940

• Ponsegromab plus chemotherapy for adults with metastatic pancreatic cancer and cachexia

  This trial tests whether adding the monoclonal antibody ponsegromab to first-line chemotherapy helps adults with metastatic pancreatic cancer who are losing weight and have fatigue from cachexia.

  Recruiting at 214 sites Phase 2/3 Pfizer · Birmingham, Alabama and 229 other locations · NCT06989437

• BBO-11818 treatment for adults with KRAS mutant cancer

  This study is testing a new drug called BBO-11818 to see if it can help adults with certain types of cancer that have specific KRAS mutations.

  Recruiting at 17 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Los Angeles, California and 16 other locations · NCT06917079

• ONT01 plus gemcitabine and nab-paclitaxel as second-line treatment for metastatic pancreatic cancer

  This trial tests whether adding ONT01 to gemcitabine and nab-paclitaxel helps people with metastatic pancreatic ductal adenocarcinoma who need second-line therapy.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT06904378

• Miami EMPIRE: Eradication of Metastatic Pancreatic Cancer with Immuno-Radiation

  This trial will try adding targeted radiation to two immune checkpoint drugs, botensilimab and balstilimab, for adults with metastatic pancreatic ductal adenocarcinoma who progressed after at least one prior systemic therapy.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06843551

• MK2 inhibitor combined with chemotherapy for advanced pancreatic cancer

  This study is testing if a new drug called Zunsemetinib can make chemotherapy work better for people with untreated advanced pancreatic cancer.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06648434

• Using advanced MRI to assess treatment response in pancreatic cancer

  This study is testing a new MRI technique to see if it can better predict how well treatment works for people with pancreatic cancer.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06600906

• Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors

  This study is testing new RAS(ON) inhibitors combined with standard treatments to see if they can help people with certain types of gastrointestinal cancers that have RAS mutations.

  Recruiting at 32 sites Phase 1/2 Revolution Medicines, Inc. · Chandler, Arizona and 31 other locations · NCT06445062

• Evaluating new treatment combinations for metastatic pancreatic cancer

  This study is testing two new treatment combinations for people with advanced pancreatic cancer to see if they can help patients live longer without their cancer getting worse.

  Recruiting at 12 sites Phase 2 Belgian Group of Digestive Oncology · Antwerp, Antwerp and 12 other locations · NCT05472259

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

• Targeted therapy for pancreatic cancer using new drugs

  This study is testing new targeted therapies for pancreatic cancer to see how well they work and if they are safe for patients at different stages of the disease.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT04005690

Related topics

Quick answers

How many Metastatic Pancreatic Ductal Adenocarcinoma clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in United States (14 trials), Australia (3 trials), China (3 trials), Belgium (2 trials), Israel (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 2: 3, Phase 1: 3, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →